Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know

<p>What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment.</p><p>In this week&#39;s On The Pen Podcast, we&#39;re breaking down one of the biggest shifts happening in obesity medicine. We dive into new research on GLP-1 persistence, the early challenges facing Medicare&#39;s obesity drug rollout, and why pharmaceutical companies are racing to solve the problems patients have been talking about for years.</p><p>We also discuss the next generation of obesity therapies, including oral GLP-1s, implantable medications, muscle-preserving treatments, and why the future of obesity medicine may be less about losing more weight and more about helping patients stay healthy for the long term.</p><p><strong>In this episode:</strong><br>• Why patients who stop GLP-1 therapy often return<br>• The first weeks of Medicare&#39;s obesity medication coverage<br>• The future of oral GLP-1 medications<br>• New implant technology from Novo Nordisk<br>• Muscle-preserving obesity treatments<br>• Why patient experience is becoming the next frontier in obesity medicine</p><p>The goal of On The Pen has always been simple: translate complex obesity and diabetes news into information that helps you have better conversations with your doctor.</p><p>👇 What has been your biggest obstacle to staying on treatment? Insurance? Cost? Side effects? Tell us in the comments.</p><p>📰 Read more obesity medicine news:<br><a href="https://onthepen.com/">https://OnThePen.com</a></p><p>📩 Subscribe to my free newsletter:<br><a href="https://obesity.news/">https://obesity.news</a></p><p>🔗 All my links:<br><a href="https://linktr.ee/manonthemounjaro">https://OTPLINKS.com</a></p><p>👍 If you found this helpful, please Like, Subscribe, and Share this episode with someone navigating obesity, diabetes, or GLP-1 treatment.</p><p>#GLP1 #Obesity #WeightLoss #Zepbound #Mounjaro #Ozempic #Wegovy #ObesityMedicine #Type2Diabetes #OnThePen #Healthcare #Medicare #Podcast</p>